Publication | Closed Access

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer

MedicineStandard ChemotherapyMetronomic TherapyClinical TrialsStage IiibPharmacotherapyCancer TreatmentMetlung TrialOncologyRadiation OncologyLung CancerHealth Sciences